Hager Biosciences is a privately-owned biopharm-aceutical company established by experienced medicinal chemists to provide pre-clinical therapeutic leads and candidates through operationally agile & effective drug discovery chemistry platforms for the pharmaceutical and biotech industries.


  • Unique and proprietary small fragment molecules
  • Modules to improve drug-like & pharmaceutical properties
  • Allows rapid med chem lead generation & optimization

While withdrawal or failure of clinical drug candidates can be attributed to multiple reasons including: commercial/market considerations, intolerable side effects, or lack of efficacy, the majority of clinical drug candidates fail due to unsuitable pharmaceutical properties (e.g.: ADME, PK, solubility, etc.). Recent strategic changes in the drug discovery paradigm incorporating early assessment of lead molecule pharmaceutical properties and concomitant development of both structure-activity-relationships (SAR) and structure-property-relationships (SPR) in advancing leads are formulated to effectively address these property-related failure rates. 

At Hager, we have strategies to deploy our unique and proprietary small molecule Fragment Pharmacophores, FragPhore™, to generate pre-clinical lead candidates endowed with desirable drug-like physical properties such as:

  • aqueous solubility
  • hydrophilic - lipophilic balance
  • rule-of-three compliance
  • atom-efficiency
  • balanced conformational properties (e.g.: flexibility & rigidity)

The unique FragPhore™ library compounds are individually designed and can feature a variety of functional groups which allow facile and efficient modular adaptation of these moieties into core molecules developed from new or existing SAR / SPR campaigns.  The utility for these drug-like fragment molecules is multi-faceted and includes:

  • improvement of physico-chemical profile of emerging leads
  • rapid identification of new medicinal chemistry leads and SAR expansion
  • enhancement of intellectual property and patent landscape
  • access to novel, clinically-validated drug-space for use in fast-follower or drug rescue strategies
  • potentially fewer SAR cycle iterations
  • risk mitigation

To best meet the needs of our clients and partners, access to the Hager FragPhore™ molecules may be accomplished on either an exclusive or non-exclusive basis.  To find out additional information on the Hager FragPhore™ Platform and to see firsthand how this approach can impact on your discovery goals, please contact us.

  • Hager Biosciences
  • ||
  • 116 Research Drive, Suite 265
  • ||
  • Bethlehem, PA 18015, USA
  • ||
  • Call: 610-849-5075
  • ||
  • Fax: 610-849-5001
  • ||
  • Email: info@hagerbio.com
  • Copyright © Hager Biosciences, LLC.